Analysts have increased their price target for SRF from $3,104.79 to $3,137.83, reflecting updated expectations for the company's financial outlook.
What's in the News
- The Chemours Company and SRF Limited have signed strategic agreements to enhance the global supply chain for fluoropolymers and fluoroelastomers (Key Developments).
- This collaboration will bolster operational flexibility and provide customers with a more reliable global supply of these essential materials (Key Developments).
- SRF’s established manufacturing capabilities, combined with Chemours’ advanced product technology, aim to deliver high-quality products to key industries, including semiconductor, automotive, aerospace, and chemical processing (Key Developments).
- The agreement allows Chemours to increase supply flexibility without requiring upfront capital investment and supplements its global operations (Key Developments).
Valuation Changes
- Fair Value: Increased slightly from ₹3,104.79 to ₹3,137.83, reflecting a modest upward revision in valuation.
- Discount Rate: Increased marginally from 13.61% to 13.68%.
- Revenue Growth: Decreased slightly from 15.28% to 15.23%.
- Net Profit Margin: Decreased marginally from 13.72% to 13.69%.
- Future P/E: Increased slightly from 42.62x to 43.29x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.